Abstract
Several studies have shown that oral contraceptive use lowers risk for epithelial ovarian cancer (EOC), but the association between use of injectable contraception (depot medroxyprogesterone acetate [DMPA]) and EOC risk has not been well studied. In a multicenter case-control study, investigators enrolled 330 women (age range, 20–70) with EOC who were …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
